Experts Predict Multiple Myeloma Outcomes Will Improve With Greater Use of Bispecific Antibodies

by | Sep 15, 2023 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Bispecific antibodies have 2 distinct binding domains, which interact with either CD3 on T cells or a tumor-associated antigen on the tumor cell surface.
Read More

Submit a Comment